This was a secondary analysis of data from the Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years ( PREVENT ) trial , a multiphase , multicenter , double-blind study in which adult outpatients with recurrent MDD ( by DSM-IV criteria ) were randomly assigned to 10 weeks of acute-phase venlafaxine extended release ( ER ) ( 75-300 mg/d ) or fluoxetine ( 20-60 mg/d ) .